Tue, Jan 27, 2015, 1:42 AM EST - U.S. Markets open in 7 hrs 48 mins


% | $
Quotes you view appear here for quick access.


  • francolaval francolaval Aug 31, 2005 2:55 PM Flag

    Restricted approval plus....

    European launch will make this stock see $12-$14 again in October/November

    FDA, IMHO, will give okay to commercialize MS-325 in November, but in a limited indication.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • A limited indication only applies when side-effects affect a sub-group of patients.
      There is no big side-effect here, only a difficulty in interpreting the images from MRI relying on different technologies.
      I dont work with MRIs but anyone here who does will confirm this.
      The FDA should interpret the data as reflecting the different state of the MRI technology available; there is more than one standard, that's it.
      There is no reason for EPIX not to get approval and get back to 25 in a few months, none.

    • There is a lot to look forward here in the next few short months...even a speculators paradise! I expect a run into the mid-teens....

    • <<FDA, IMHO, will give okay to commercialize MS-325 in November, but in a limited indication. >>

      What kind of labeling are you anticipating?

      • 1 Reply to jfitisoff
      • MRA of the abdominal vessles - or MRA of the renal arteries. The pivotal studies in this indication are quite unequivocal. Then, they may ask to do a comparative trial MS-325 in an MRA indication (or multiple MRA indication) versus current 0.5M standard. BUT, what's strange in all of this is that the FDA had given them approval of their plans many years ago, stating their current trial design was okay - but, they've seem to have changed their minds. I think there will be some pressures on the FDA to get their act together and approve this agent.

0.00010.0000(0.00%)Oct 25 11:34 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.